Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$50.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$50.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$15.80 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)834.26K
Market Cap
$3.79B
Enterprise Value$2.28B
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$5.79M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding71,074,520
10 Day Avg. Volume733,114
30 Day Avg. Volume834,256
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.87K
Enterprise Value/Ebitda-13.59
Forecast
1Y Price Target
$110.17Price Target Upside117.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.44
Revenue Forecast (FY)$35.71M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Low LeverageA large equity base and negligible debt provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. This lowers short-term default risk and supports continued R&D investment while the company advances late-stage trials toward potential commercialization.
Compelling Phase 2 Obesity Data And Phase 3 PathRobust Phase 2 results plus positive FDA end-of-Phase-2 feedback materially de-risks the lead program and support a defined clinical development timeline. Advancing a differentiated oral obesity candidate to Phase 3 strengthens future commercial prospects and strategic partnership or licensing opportunities.
Strengthened Operational LeadershipAdding an experienced COO/GC with proven commercialization and transaction experience improves the company’s ability to run large global Phase 3 programs, negotiate partnerships, and prepare for launch or strategic exits — a durable enhancement to execution capability.
Bears Say
Pre-revenue With Widening Operating LossesThe company remains without product revenue and losses have materially widened over recent years, meaning long-term viability depends on successful clinical outcomes or sustained financing. Persistent negative earnings limit reinvestment and increase reliance on external capital over multiple years.
Heavy And Persistent Cash BurnConsistent negative operating and free cash flow, with accelerating FCF deterioration, creates ongoing funding needs. Even with current capital, sustained burn trends force continued capital raises or partnerships, constraining strategic optionality and increasing execution risk if clinical timelines slip.
Dilution Risk From Expanded ATM CapacityUncapped ATM capacity materially increases the likelihood of equity issuance to fund operations, which, while improving financing flexibility, creates a durable dilution risk for existing shareholders and signals dependence on public markets to finance multi-year clinical programs.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $15.80 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.79B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 22 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 07, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.001.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.38.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,074,520 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -0.128%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.17 (117.08% Upside)
$110.17 (117.08% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 475.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
182.32%
12-Months-Change
Fundamentals
Return on Equity
-15.14%
Trailing 12-Months
Asset Growth
74.04%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$110.17
▲(117.08% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
26.29% Mutual Funds
0.08% Other Institutional Investors
61.75% Public Companies and Individual Investors